重组改构人肿瘤坏死因子联合NP方案治疗晚期非小细胞肺癌的临床研究  

The effect of rmhTNF-α combined with chemotherapy in the treatment of patients with non-small cell lung cancer

作　　者：穆海玉[1] 沈春燕[1] 胡素萍[1] 

机构地区：[1]中国武警医学院附属医院肿瘤科,天津300162

出　　处：《临床肿瘤学杂志》2008年第10期884-887,共4页Chinese Clinical Oncology

摘　　要：目的:观察国产注射用重组改构人肿瘤坏死因子(rmhTNF-α)联合化疗与单纯化疗治疗非小细胞肺癌(NSCLC)的临床疗效和不良反应。方法:随机将47例NSCLC患者分为试验组和对照组。对照组仅给予NP方案(长春瑞滨+顺铂)化疗,而试验组在给予NP化疗的同时,分别在第1～7天和第11～17天肌肉注射rmhTNF-α4MU/m2,两组均21天为1周期,化疗2周期后评价有效率、KPS评分和不良反应。结果:试验组1例因病情进展放弃治疗,余28例均完成2周期治疗。试验组有效率为57.14%,对照组有效率为22.22%,两者之间有显著性差异(P<0.01)。试验组治疗后KPS评分显著高于对照组(P<0.05)。不良反应方面,试验组出现轻中度发热、感冒样症状、注射局部疼痛的例数较对照组增加(P<0.01),但症状均可耐受,并在给予对症治疗后消失。结论:rmhTNF-α具有良好的抗肿瘤和与NP方案化疗协同作用,可显著改善患者的生活质量,是一种安全有效,可以使晚期NSCLC患者获益的药物。Objective：To evaluate and compare the efficacy and toxicity of rmhTNF-α combined with chemotherapy in the treatment of patients with non-small cell lung cancer（NSCLC）.Methods：Forty-seven patients with NSCLC were randomly devided into trial group and control group.Chemotherapy with NP regimen was given to the patients.Meanwhile,rmhTNF-α injection of 4MU/m^2 was also given to the patients of trial group from the 1st to 7th days,the 11th to 17th days.Twenty-one days were as a cycle,2 cycle were given to each patients.The efficacy and toxicity were observed and compared between the two groups after the therapy.Results：The response rate of therapy were 57.14% in the trial group,and 22.22% in the control group,respectively（P〈0.01）.The KPS scores after the therapy was 86.42±7.43 in the trial group,and 77.23±7.92 in the control group（P〈0.05）.The side effects related to rmhTNF-α included fever,cold-like symptoms,and pain in the injection site.All of them disappeared after the correct therapy.Conclusion：The efficacy of rmhTNF-α combined with chemotherapy is remarkably higher than that of chemotherapy alone in the treatment of NSCLC.rmhTNF-α can improve the quality of life of the patients with slight toxicity.

关 键 词：非小细胞肺癌 重组改构人肿瘤坏死因子 化学治疗 毒性 

分 类 号：R730.51[医药卫生—肿瘤]